Clinical trial
ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness…
NCT00440479 · Janssen-Cilag B.V., Industry · Completed
Key facts
| NCT number | NCT00440479 |
|---|---|
| Title | ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. |
| Official title | An Observational Study To Determine Velcade (Bortezomib) Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies (ADVANCE) |
| Lead sponsor | Janssen-Cilag B.V., Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Multiple Myeloma, Hematological Neoplasms |
| Intervention type | Drug |
| Interventions | Bortezomib |
| Enrollment | 11 |
| Start date | Sep 1, 2006 |
| Primary completion | Jan 1, 2011 |
| Completion | Jan 1, 2011 |
| First posted | Feb 27, 2007 |
| Last update posted | Apr 16, 2015 |
| Countries | Netherlands |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: